J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (23)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, J. J.
Right arrow Articles by Swope, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, J. J.
Right arrow Articles by Swope, D. M.

THERAPEUTIC REVIEW

Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease

Jack J. Chen, PharmD, BCPS, CGP and David M. Swope, MD

From the Movement Disorders Center, Loma Linda University, Loma Linda, California (Dr Chen, Dr Swope), and the Department of Pharmacy Practice, Western University of Health Sciences, Pomona, California (Dr Chen).

Rasagiline is a novel second-generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B). For the management of Parkinson disease (PD), rasagiline is efficacious across the span of PD stages ranging from monotherapy in early disease to adjunctive treatment in patients with advancing disease and motor fluctuations. Rasagiline completely and selectively inhibits MAO-B with a potency 5 to 10 times greater than selegiline. Unlike the prototype propargylamine selegiline, which is metabolized to amphetamine derivatives, rasagiline is biotransformed to aminoindan, a non-amphetamine compound. Rasagiline is well tolerated with infrequent cardiovascular or psychiatric side effects, and at the recommended therapeutic dose of up to 1 mg once daily, tyramine restriction is unnecessary. In addition to MAO-B inhibition, the propargylamine chain also confers dose-related antioxidant and antiapoptotic effects, which have been associated with neuroprotection in multiple experimental models. Thus, in addition to symptomatic benefits, rasagiline offers the promise of clinically relevant neuroprotection.

Key Words: Monoamine oxidase • neuroprotection • Parkinson disease • propargylamines • rasagiline

Address for reprints: Jack J. Chen, Western University of Health Sciences, College of Pharmacy, 309 E. Second Street, Pomona, CA 91766.




This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
J. J. Chen
Duplicate publication
Am. J. Health Syst. Pharm., December 1, 2006; 63(23): 2310 - 2310.
[Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
A.-V. Ly
Duplicate publication
Am. J. Health Syst. Pharm., December 1, 2006; 63(23): 2310 - 2310.
[Full Text] [PDF]

Home page
 NeurologyHome page
U. Bonuccelli and P. Del Dotto
New pharmacologic horizons in the treatment of Parkinson disease.
Neurology, October 10, 2006; 67(7 Suppl 2): S30 - S38.
[Abstract] [Full Text]

Home page
 Am J Health Syst PharmHome page
J. J. Chen and A.-V. Ly
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease
Am. J. Health Syst. Pharm., May 15, 2006; 63(10): 915 - 928.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Clinical Pharmacology